Article

Antidepressant Works in Treating Painful Neuropathy

Author(s):

Patients who experience chemotherapy-induced peripheral neuropathy may find relief with the antidepressant Cymbalta.

Patients who experience chemotherapy-induced peripheral neuropathy (CIPN), an often painful side effect that can involve numbness and tingling in the hands and feet, may find relief with the antidepressant Cymbalta (duloxetine), according to results from a phase 3 study. Although currently approved for the treatment of diabetic peripheral neuropathic pain, Cymbalta is the first drug that has proven effective in treating CIPN.

Experienced by about one-third of patients treated with taxanes and platinum-based chemotherapy, CIPN can develop weeks, months or years after treatment. Symptoms generally resolve completely, although healing of damaged nerves can take a few weeks to many months or even years.

In the study, 231 patients who had previously reported high levels of pain from CIPN were randomized to one of two arms. Participants in Arm A received Cymbalta for five weeks. After a one-week “washout” period, they received a placebo for five weeks. Participants in Arm B did the opposite, beginning with a placebo and ending with Cymbalta. Researchers reported a statistically significant decrease in pain for those taking Cymbalta in the initial treatment period. The most common side effect was fatigue.

Unfortunately, the drug didn’t work for everyone, which presents the next challenge, says lead investigator Ellen Lavoie Smith, PhD, APRN, AOCN, of the University of Michigan School of Nursing. “We’ll try to identify who will respond so we can target this drug to those who are most likely to benefit.”

Newsletter

Stay up to date on cancer updates, research and education

Related Videos
Waldenstrom macroglobulinemia is often slow growing, with high survival but lower quality of life over time, explained researcher Alisha Kimble.
Image of woman.
Image of two doctors and text.
Combining JNJ-1900 with Keytruda may improve distant control of lung cancer, explained by Dr. Jared Weiss.
image of serzan.
Dr. Breelyn Wilky explains that personalized treatments are helping improve outcomes for patients with gastrointestinal stromal tumors.
Image of two doctors with text.
Image of doctors with text.
Imiage of two doctors with text.
Treatment with zanzalintinib plus Opdivo and Opdualag is an option worth exploring in patients with previously untreated clear cell renal cell carcinoma
Related Content